Relay Therapeutics shared interim data for zovegalisib at SABCS 2025, showing consistent efficacy in breast cancer patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback